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MRL/ I mice develop progressive, virulent autoilnmune dis-
ease that has many of the features of systemic lupus erythema-
tosus. Prophylactic treatment of MRL/I mice with syngeneic 
photo inactivated autoimmune splenocytes improves survival 
and inhibits the fuhninant hyperproliferation of abnormal T 
cells and the production of high titer anti-DNA antibody 
invariably found in untreated mice. The proliferation of Thy 
1 + splenic T cells was sigllificantly decreased, and prolonged 
T he MRL/ I mouse model of systemic lupus erythema-tosus provides an experimental system that permits exploration of the effect ofT -cell directed therapcutic maneuvers on the course of autoimmune disease. MRL/ I mice develop lymphoid hyperplasia, B-ccll 
hypcractivity, autoantibodies, circulating imlllune complexes, de-
pressed serulll complement, thymic cortical atrophy [1,2], derma-
ritis [3 .4]. arthritis [S,6}. and fatal immune complex glomerulo-
nephritis. The genome of the MRL/ l mouse contains the autosomal 
recess ive mutation Ipr. Homozygosity for this gene results in early 
onset of autoimmune disease with massive lymphadenopathy and 
splenomegaly duc to a proliferation of phenotypically aberrant 17-
9}, functional inducer T cells [1 OJ. Initiation of autoimmune diseasc 
in these mice correlates with the onset ofT-ceil hyperproliferation. 
suggesting that the primary defect in this model relatcs in a misre-
gulation of inducer T cells resulting in polyclonal B-cell stimula-
tion. 
Therapies that ablate T cells can improve some of the parameters 
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retemion of the response to T-cell mitogen was found in 
treated mice. Treatment with unmodified cells induced a 
partial inhibition of disease features which did not prolong 
survival rates. These results suggest that phototherapy po-
tentiates a normal immunoregulatOry process which enables 
suppression of the development of abnormal cell populations 
in young MRL/ l mice with relatively intact im_mune sys-
tems.] bIVes! Derma '01 94:52-57, 1990 
of auroinllnullC disease thar arc invariably manifested. In an age-
related fashion, in untreatcd MRL/ l mice [11.121. Neonatal thy-
mectomy [131; injection of monoclonal antibodies directed against 
the pan T-cell marker, Thyt [11], or the inducer T-cell marker, 
L3T4 114]; .nd tOtal lymphoid irradiarion [15] of MRL/I mice 
prevented the development of autoimmune disease. increased sur-
vival, and depressed T-cell proliferation. 
Photochemothcrapy [t 6] is a new treatment modality that may 
provide a clinically practical method to promOte T-cell regulation 
through exposure of the recipient to autologous, photomodifled 
lymphocytes using the drug 8-methoxypsoralen (8MOP) activated 
by ultraviolcl A (UVA) light to form a DNA crosslinking .gent 
[171. Lymphocytes treated in this fashion fail to proliferate after 
stimulation by mitogen. antigen or alloantigen, but retain the capac-
ity to serve as srimularor cells in mixed leukocyte culture. The 
photo inactivated cells dic gradually in vitro over a S-d interval [18]. 
Photochcmotherapy has recently bcen demonstrated ro be effica-
cious in the management of patients with the leukemic phase of the 
aggressive inducer T-cell malignancy. cutaneous T-cell lymphoma 
(CTCL) [16]. One mech.nism by which phorochcmorherapy may 
achieve a beneficial effect in CTCL patients is through induction of 
an autoregulatory response in the recipient, putarively directed 
against abnormal T-cell idiotypes expressed on the reinfused lym-
phocytes. 
If photochemodlcrapy invokes a host response that regulates ab-
normal inducer T-cell expansions, this approach could be studied in 
the MRL/I mouse model where a phenotypically aberrant, benign 
helper T-cell hyperproliferation promotes the development of au-
toimmune disease. To test whether reinfusion of phoromodified 
lymphocytes can altcr the course of a fulminant autoimmune pro-
cess, recipient mice were exposed to syngeneic autoimmune spleno-
cytes prior to the onset of overt disease when a relatively intact 
immune system was present. Treated mice were monitored by eval-
uation of reliable indicators of disease progression, including 
lymphoid organomegaly. survival, lymphocyte phenotype, and 
anti-DNA antibody rroducrion. Control groups were untreated or 
received injecrions 0 unmodified autoimmune cells or lysed photo-
treated cells to determine if the therapy was contingent on the 
presence of intact effector ce lls of the autoimmune process. The 
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results obtained demonstrated a marked reduction in lymphoid hy-
perproliferation, prolonged survival, altered splenic lymphoid pop-
ulations. and decreased production of anti-DNA antibodies in the 
recipients of phototreated autoimmune cells. Injection of unmodi-
fied cells alone was partially eifeC[ive, while damaged cells had no 
effect, indicating that intact effectOr cells are required for induction 
of a response. The onset of autoimmune disease, as measured by 
these parameters. was sign ificantly delayed in treated mice by 
preexposure to autoimmune effector cells. 
MATERIALS AND METHODS 
Mice Because the onset of the disease process is slightly earlier in 
female MRL/l mice {2], male mice were selected for study to insure 
an adequate opportunity for therapeutic intervention. Young male 
MRL/MpJ-lpr/lpr mice were obtained from Jackson Laboracories 
(Bar Harbor, ME) at 4-6 weeks and used as recipients of photoinac-
tivated auwimmune splenocytcs or age-matched untreated controls. 
Donor male M RL/I mice were retired breeders received at 17 - 2 J 
weeks. BALB/c mice were used as normal controls and werc re-
ceived from Jackson Labs at 6- 7 weeks. 
Cells Spleen cell suspensions were prepared under sterile condi-
tions. Splenocytes were liberated by macerating the spleens in a 
sterile petri dish with forceps. The cells were washed in Hanks 
buffered sale solution (HBSS, Gibco Laboratories, Grand Island. 
NY). and red blood cells were lysed with ammonium chloride 
(0.83%, in water) at 4°C for 10 min. The cells were washed and 
resuspended in RPMl 1640 (Gibeo) containing 5% fetal calf serum 
(FCS) for culmre or phosphate-buffered soline (PBS, Gibeo) for 
treatment with 8 MOP-UVA. Lymph nodes were obtained from 
the retroperitoneal area and prepared in a similar fashion. Lymph 
node size was determined by measuring length and width with a 
ruler. 
8 MOP-UV A Protocol The optimal concentration of 8 MOP 
(Elder. Bryan. OH) and dose of UVA for inhibition of lymphocyte 
proliferation was determined by development of a dose-response 
curve (dora nOt ~resented). A drug level of 100 ng/ml and a light 
dose of 1 joule U)/cm ofUVA energy were selected to phoroinacti-
yare the splenocytes. 
The autoimmune status of the donor MRL/I mice was confirmed 
by demonstration of humoral anti-ON A antibody or the presence of 
overt lymphoid organomegaly. Splenocytes (20-50 X 106/ml) 
were incubated with 100 ng/ml ofa MOP in PBS at 23'C, for 20 
min prior to irradiation with 1 j/cm2 UVA. The light source con-
sisted of a bank of four black lights (FL40, Sylvania GTE Products. 
Danvers, MA) emitting broad spectrum UVA energy (320 - 400 
nm). filtered through a sheet of window glass to remove uva 
emission. The light dose was calculated after measuremenc with a 
specrrophotometer (IL700A, International Light, Newburyporc. 
MA). Previously performed controls included cells exposed to UVA 
alone or shielded with foil and placed on the irradiation surface 116]. 
These controls demonstrated that human lymphocytes as well as 
murine lymphocytes were viable at the time of reinfusion, but died 
gndually over a 5-d interval in vitro and lost the capacity to respond 
to mitogens because of crosslinking of their DNA by photoaddition 
of 8-methoxypsoralen. 
After irradiation, the cells were washed. resuspended in PBS at 
20 - 50 X 10' splenocytes/100 .ul, and injected intravenously into 
the tail vein of recipient MRL/I mice. The viability of the photo-
treated cells was 90% or greater as de tennined by trypan blue exclu-
sion. Mice received their first injection at 6 weeks of age. a time 
point rhat is prior to the initiation of Inost of the features of the 
autoimmune process {19]. The mice were treated at 2-week inter-
vals until conclusion of the experiment. In some protocols, groups 
of mice were treated in parallel with autoimmune splenocytes with-
out 8 MOP-UVA inactivation or autoimmune cells that had been 
rapidly frozen and thawed to induce lysis. These mice received the 
equivalent number of whole or lysed splenocytes as the 8 MOP-
UV A experimental group. 
PHOTOTHERAPY OF MURINE SlE S3 
Radioimmunoassay for Anti-Double Stranded DNA Anti-
bodies A solid phase radioimmunoassay (RIA) was performed 
using calf thymus DNA (Sigma. Chemical Co., St. Louis. MO) at a 
concentration of t mg/ml in PBS. The DNA was sonicated for 30 
min to obtain small fragments and aliquoted (100 III/well) into the 
wells of a round bottom micfOriter plate (Flow Laboratories. Rock-
ville. MD). The wells were coated with the DNA solution by rota-
tion on a plate shaker (Dynarech Laboratories. Alexandria, V A) for 
J It at 23 °C. The pbte was air-dried overnight in a laminar flow 
hood. The details of the RIA assay have been previously described 
[20]. Calf thymus DNA might comain some degree of single-
stranded DNA which could result in some detection of autoanti-
body to both single- as well as double-stranded DNA. However. the 
final concentration of DNA in the wells was approximately 50 
.ug/well and any single-stranded DNA contamination at this level 
would represent a minor component of rhe DNA present. 
Pbenorypic Analysis Monoclonal antibody analysis was per-
formed to determine the phenotype of splenocytes in treated mice 
and comrol animals. Spleen cell suspensions were prepared and 
resuspended in RPMI 1640 containing 0.3% bovine serum albumin 
(BSA). The al1ti-T-cell monoclonal antibodies used were anti-LYT 
1.2.2. t ,3.2, Thy 1.2, Iak, and IJI.. (Cedarlane Laboratories. Omario, 
Canada). These antibodies were produced in mice. and use of a 
fluoresccin-col~lIgated rabbit anti-mouse 19G or IgM secondary 
reagent reqilJfed preliminary lysis of surface immunoglobulin-posi-
tive B cells. To lyse the B cells. the splenocytes were incubated at 
10 X t06 cells/ 1Il1 with a J: 20 dilution of the rabbit anti-mouse 
IgG or as a control nonspecific mouse ascites fluid in RPMI/3% 
aSA for 30 min at 4°C. The cells were resuspended in 2 ml of a 
1: 20 dilution of rabbit complement (Cedarlane Laboratories) and 
incubatC'd at 37°C for 60 min. The cells were washed twice and 
resuspended in RPMI/3% BSA for assessment of viability by trypan 
blue exclusion. Non-viable cells were removed by flotation 011 
Lympholyte-M (Cedarlane Laboratories) and centrifugation 
(500 X g, 20 min. 23 °C). Indirect immunofluorescence analysis 
was performed as previously dcscribed 120). 
Mitogen Assays Splenocytes were adjusted to 5 X 106 cells/ml in 
RPMI 1640 containing 5% FCS. The cells were ali quoted at 100 
Ill/well in five replicate wells of a flat-bottom microtiter plate 
(Flow Laboratories). Background cultures received lOO.u1 of RPM I 
1640/ 5% FCS. Stimulated cells received 100 III of a 4-lIg/1111 solu-
tion of concanavalin A (Con A. Sigma). Splenocytesstimulated with 
lipopolysaccharide (LPS. Difco Laboratories. Detroit. MI) received 
100 III of:1 100 .ug/Illl solution. Cultures were incubatcd for 3 d at 
37°C under a 5% C02 atlllosphere. The cultures were pulsed with 1 
.uCifwcll oflH-thytnidine (Amersham, Aclington Heights. JL) and 
harvested 12- 18 h later with a Mash II automated harvestor (Whit-
eaker M. A. Bioproducts, Walkersville, MO). The samples were 
counted ill a liquid scintillation Beta countcr (Amcrsham Corp.). 
Statistics The weight, size, and cellularity of organs obtained 
from the groups of mice were analyzed for statistical significance by 
the standard Student t test. Survival data were analyzed using a z 
statistic to reject the null hypothesis at the a '"'"' 0.01 level of signifi-
cance. 
RESULTS 
Reduced Lymphoid O.ganomegaly in T .. ated MRL/ I 
Mice The weight and size of lymph nodes obtained from mice 
receiving bi\\'eckly injections of photoinactivated splenocytes from 
autoimmunc donors (N - 29) was compared to organs obtained 
from age-matched Httermates m~ated with unmodified autoim-
mune cells (N = 8) or umreated controls (N = 97. Fig I). The 
weight and size of retroperitoneal lymph nodes obtained from mice 
treated with photoinaccivated autoimmune splcnocytes was signifi-
cantly (p < 0.001) reduced in comparison with untreated comrols 
at every age ~rudied. A similar decrease in lymph node weight (p < 
0.025) and size (p < 0.005) was demonstrated in young mice and 
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Figure 1. Comparison of the weight and Size of retropcmollcal lymph 
1l000Ies oblCiined from age.matchcd MRL/ I mice rreOited with photoinacti-
vated splenocytcs (bldCit bars) , unmodified autoimmune: cells (wlritt' bem) , 
2nd untreated controls (striprJ bars). Rcsulu arc presented as the mc.an ± the 
st:l.ndard error. Older Illice treated with unmodified :mtoimmunc cells were 
studied unlil 26 weeks 
maintained in the lymph nodes obtained from older mice (wt: p < 
0.0 I ~ size: p < 0.001) treated with unmodified aucoimmune cells. 
Figure 2A demonstrates rhat spleens obtained from the recipienrs 
of photoinacrivated autoimmune splenocytes (N ""33) showed a 
significant (p < 0.001) reduction in weight and size when com-
pared to controls (N = 121) at an early age (7 - 8 weeks). The 
splecns obtaincd from 19 - 34-week treated m.ice were increased in 
weight and size but remained reduced in comparison co the un-
treated age-matched controls (wt: p < 0,01. size: p < 0.025), 
MRL/I mice treated with unmodified autoimmune cells (N - 13) 
did not demonstrate a decreased splenic weight at a young age. 
Older mice in this group had significantly smaller spleens when 
compared [0 controls (p < 0.00 I). 
The cell yield obtained from the splcens of mice treared with 
photoinactivated autoimmune splenocytcs (N - 20) was signifi-
cantly reduced in both young (p < 0,001) and old mice (p < 0,005) 
in comparison to comtois (N = 100, Fig 2B). Mice receiving un-
modified autoimmune cells (N = 9) also had reduced splenic cellu-
larity (p < 0.01). In the group of 46 mice that received photoinacti-
vated autoimmune cells, only four mice (9%) were judged to be 
treatment failures based 011 early onset of lymphoid organomegaly. 
In contrast, 20% of the mice tested in the group receiving cells 
without inactivation were judged to be treatment failures. 
An additional group of mice were recipients of photoinactivated 
autoimmune cells that had been lysed by freezing and thawing prior 
to injection (results flor shown). These mice exhibited rapid onset of 
organomegaly (16- 20 weeks) and died at an early age (60% mortal-
icy by 16 weeks of age), 
Survival The survival of mice treated with injections of photoin-
activated autoimmune splenocyces was compared with the survival 
of mice [redced with unmodified cells or uncreated controls (Table 
I). The group of mice that received unmodified cells from autoim-
mune donors demonstrated 50% mortdJity by 20 weeks of age. The 
50% mortality level was reached in untreated control mice at 23 
weeks of age. This rate of control mortality is similar to that re-
ported in other studies [191. In contrast, twice as many of the recipi-
ents of photoinactivated autoimmune splenocytes were alive at 23 
weeks of age. The increased survival demonstrated in the recipients 
of photorreatcd splcnocytes was statistically significant in compari-
son to the controls (a = 0.01) and was maintained from 23-29 
weeks, at which time all of rhe untreated control mice had died. The 
survival of the phototreated splenocyte group was significantly 
(a = 0.01) prolonged compared to the recipients of unmodified 
cells at 23 and 26 weeks. 
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Figure 2. A : Comparison of the weight and size of spleens obtained from 
age-marched MRLjl mice lre:ned with phoroinactlvated autoimmune 
splcnocytes (bla(k bars) . unmodif1ed autoimmune cells (whitt bars), and un-
treated controls (striped bars) . Results 2re presented as the mean ± standard 
error. Older mice treated with ullmodif1ed autoimm une cells were studied 
until 26 weeks. 8 : Comparison of the yield of splenocytes obtained from the 
spleens of MRL/I mice treated With phototnactivated 2utoimmune spleno-
cytes (black bars), unmodified 2utolll1mUne cells (whil~ luIrs), and untre2ted 
control s (slri/NJ bars). Results are presented as the mean ± st2ndard error. 
Older mice treated with unmochf1ed autoimmune cells were studied uIltil26 
weeks. 
Table J. Survival of MRL/I Mice Treated with 
Phmoillacrivated Autoimmune Splenocytcs, Unmodified Cells or 
Untreated Controls 
Surviv:al (%) 
8 MOP-UVA cells Unmodified cells None 
Ag' (w«ks) (N - 22) (N ~ 20) (N -20) 
II 100 100 100 
14 90 96 95 
17 84 96 85 
20 69 50 70 
23 59- 23 25 
26 30- 9 20 
29 15' 9 0 
32 7 5 
35 3 0 
37 0 
• Sutiulcally sIsnificant Incrcas~d surVival .1.1 the n- 0.01 l~Yd In the 8 MOP·UVA 
cdl rC("lpu'fI( gro up compared to the unmoolnrd cdl reCIpients (23 ;I.nd 26 wedu) and 
tbe non· m::lled group (23 . 26. llld 29 weeks). 
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Table II. Anti-d, DNA Antibody Levels in MRL/ I Mice 
Treated with Photoinactivated Autoimmune Splenocytes, 






AntiMds DNA antibody (CPM) 
8 MOP-UVA T x cells 
(N-5. 
X ±SO) 
90 1 ± 858 
1971 ±772 
Untreated controls 
(N - 10. 
X ±SO) 
6355 ± 733 
15063 ± 4482 
• Norm.:a l.sefl wrrC' obuuu~d froll1 BAUJ/c or C UA/J lIliu. 
Normal mIce-
(N - 10. 
X ±SO) 
2353 ± 670 
Effect of Reiofused Pbotomodi6ed Splenocytes 00 Anti· 
DNA Antibody The development of autoantibodies to clouble-
stranded DNA was followed ovcr t ime in MRL/ I mice that received 
photoinacdvatcd autoimmune splenocytes in comparison to un-
treated controls (Table II). Sera from normal BALB/c mice were 
studied as an additional control to ascertain background levels of 
anri-DNA antibody. Untreated control MRL/ I mice had high 
levels of anti-DNA antibody at 13 :loIld 17 weeks of age, Mice that 
were recipients of photoinactivated splenocytes had low senlm 
levels o f anti-DNA antibody at 13 weeks. At 19 weeks of age, the 
amibody level in mice that were recipients of photoinactivated au-
toimmune splenocytes was in the background range found in nor-
mal strains of mice, 
Phenotype ofSplenocytes from Mice Receiving Injections of 
Autoimmune Spleoocytes Splenocytes were obtaincd from 
micc rcceiving injcctions of photoinactivated autoimmune spleno-
cytcs at 13 - 26 weeks of age (Fig 3). Splenocytes from recipients of 
untrcated autoimmune splenocytes and control mice were also stud-
ied. T o adjust for tile marked lymphoid depletion in the treated 
spleens, the results were expressed as the absolute number of anti-
body- reactivc splenocytes as determined by adjusting the number of 
recovercd splenocytes by the percentage of cel ls stained with each 
antibody, Thc splecns of mice treated with photoinactivated au-
toimlllune splcnocytes contained a non-significant decrease in B-
lymphocytes bearing surface immunoglobulin in comparison with 
the recipients of unmodified cells or the untreated controls. The 
abso lu te numbcr ofTily 1.2+ T cells was significantly reduced (p < 
0.00 t) in rhe phocoinactivated ce ll treated group. The recipients of 
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Figur~ 3. Comparison of th e absolute number of antibody positive cd ls 
obtamed from the spleens of MRL/ I mice treated with photoin::activated 
autoimmune splenocytes (bla(k btlrs), unmodined autoimmune cells (wh itt 
blltS). or untreated controls (striped bars) . The percentage of positive cells was 
derennincd by indirect immunofluorescent staining and analyzed by cyto-
fluorograph y. The total number of ce lls per spleen was multiplied by the 
percenta ge of reactive cdls to obtain the absolute number of posifive cells. 
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in the absolute number of splenic T cells but not co the extent 
demonstrated in the spleens of mjce treated with photomodified 
au toimmune cells (p < 0.001). The LVt+ splenocyte population 
was reduced in che spleens of mice receiving photomodi6ed (p < 
0.025) or untreated autoimmune splenocytes. 
Response to LPS and Con A Splenocytes from mice that had 
received injections of phocomodified or umreated am oiml11une cells 
were studicd at various rime points to determine their capacity to 
respond CO LPS and Con A in comparison to 2ge-matched liner-
maces. Uccause the treated mice had substantially fewer T cells than 
the controls, the results wcre adjusted to reflect the absolute number 
of B orT cel ls availab le for stimulation. In Fig 4A , the response ofB 
ce lls to LPS stimulation from the three groups of mice is presented . 
Thc splenic B cells from the photoinactivated autoimmune cell 
treated mice were slightly less responsive to LPS stimulation than 
4 
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Figu.re 4. A : Comparison o( the response to lipopolysaccharide ofindivid-
ual B lymphocytes obta.ined from the spleens o( age-matched MRL/ I mice 
treated with phOtoinactivaced autoimmune splenocytes (thi" solid Ii"" with 
bla(k squares), unmodified autoimmune cells (dotud litlt with stars). or un-
treated controls (thick solid liM with crossa) . The results were calculated by 
diViding th e totoll cpm by rhe absolute number of Sig-positive B cells as 
determined by indirect immunofluorescence. For each experimental group a 
bc~t fit trend line was drawn. B: Comparison of the responu- of individual T 
lymphocytes obtained &om the spleens of age-matched MRL/I mice treated 
with photoinactivated autoimmune splellocytes (thit! roUd lim.' utith bia(k 
sqllarts), unmodified aU[oimm une cel ls (dotttd litl" with stars), or untreated 
controls (thick solid Ii"" with (roUtS) to concanavalin A. The results were 
calculated hy dividing the toraJ cpm by the absolute number of Thy t-posiM 
rive T cells as determined by indirect immunofluorescence. For each experi-
mental group a best nl trend line was drawn. 
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controls. The recipients of unmodified autoimmune cells had an 
equivalent number ofB cells when compared recantrals (Fig 3), but 
these cells responded poorly to LPS in comparison to B cells ob-
tained from control MRL/I and the recipients of photoinactivated 
cells. Over time, the capacity to respond to LPS was lost in all three 
groups. In Fig 4B, rhe response to Con A of splenic T cells from all 
three groups of mice (adjusted to reflect the absolute number ofT 
cells) is presented. Although the absolute number of T cdls was 
significantly reduced in the group of mice receiving photoinacti-
v:lrcd splenocytes (Fig 3), the residual T cells responded better [0 
Con A stimulation (p < 0.025) than T cells from the recipients of 
uncreated autoimmune cells or controls. At older ages. thc rcsponse 
to Con A was lost in all groups. 
DISCUSSION 
This study demonstrates that rhe fulminant progression of the au-
toimmune process in the MRL/l mouse may be ameliorated by 
exposing the animal at an early age to syngeneic lymphocytes from 
actively autOimmune mice. The inhibirion of the disease process 
attained is comparable to the results achieved by othcr forms of 
anti-T cells therapy [1 1-151 but docs not involve delivery of sys-
temically toxic agents. These results indicate that treatment with 
autologous lymphocytes may provide an alternative form of clini-
cally feasible immunorcgulation that can prevent T-cell hyperpro-
liferation and autoantibody formation. 
Three groups of mice were evaluated in this study. The recipiems 
of unmodified autoimmune cells represented a parallel treatmem to 
the photolllacrivated group. These mice were exposed to rhe rcle-
vam T-cell idiorype on the autoimmune cells at an age when their 
immune system mighr retain the competence to respond to this 
abnormal expansion of autoreactive cells. Photoinactivation was 
demonstrated to enhance the host response to injection of this effec-
tor T-cell population. 
Analysis of bath lymph nodes and spleens from mice treated with 
either photoinactivated or unmodificd autoimmune lymphocytes 
demonstrates that a significam reduction in lymphoid organomeg-
aly can be:Jchicved and maintained by this protocol. Lymphadenop-
athy has been found to he a reliable indicator of disease activity in 
the MRL/l mouse [19.21]. Mice treated with unmodified as well as 
photoinactivated autoimmune splenocytes demonstrated a 50% re-
duction in lymphadenopathy. This decrease in lymph node size and 
weight was maintained beyond the normal life span of untreated 
littermates, in recipients of photoinactivaced cells. Recipients of 
unmodified cells did not demonstrate decreased splenomegaly ulttil 
late in their trea.tmenr course, indicating that injection of unmodi-
fied cells may be relatively less effective than phototreated cdls. 
The survival resules indicate that injection of unmodified autoim-
mune cells docs nOt prolong survival and may in some animals result 
in earlier death. In contrast. only 9% of the recipients of photo-
modified autoimmune cells developed early disease. and the major-
ity of these mice survived significantly longer than the untreated 
controls. The requirement for intact cdls in this treatment regimen 
was indicated by the resules of a group of mice that received lysed 
photoinactivated autoimmune splenocytes. These mice died rapidly 
with manifestations of aggressive autoimmune disease. 
Treatment with photoinactivated autoimmune splenocytes not 
only decreased lymphoid hypcrproliferation and increased survival 
bur also prevented the induction of anti-DNA antibodies. The pos-
sihility rhat this inhibition of autoantibody production was related 
to a depletion of rhe abnormal T-cell population found in untreated 
MRL/I mice [22,23J was supported by phenotypic analysis of the 
splenic populations of treated mice. No significant difference in the 
absolute number of B cells was found in the spleens of treated micc 
in comparison to controls. The T-cell population was significantly 
reduced in the spleens of treated mice. conlirtning chat this form of 
therapy is mainly T-cell directed and suggesting that inhibition of 
T-cell hyperproliferation can primarily or in conjunction with dc-
piNion of a relevant B-cell subset result in suppression of autoanti-
body production. The limited reduction in T cells found in the 
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spleens of mICe treated wirh ul1modified autoimmune cells suggests 
that phoroinactivation significantly enhances the ability of synge-
neic cell populations to inhibit the onset of autoimmune disease in 
these mice. 
Mitogen assays of the T - and B-cell compartments of treated mice 
and controls demonstrated that B cells from treated mice responded 
to a slightly lesser degree than cOl1trols to lPS stimulation. A signif-
icant improvement in the observed T-cell hyporesponsiveness to 
the mitogen Con A [24,251 was found in tite spleens of mice rreared 
with photoinactivated autoimmune splenocytes. This increased re-
sponse was found in the residual T-cell population in treated spleens 
and may reflect retention of a normal T-cell subset. Alternatively, 
an autoregulatory T-cell population present in these spleens may 
have an increased capacity to respond to this mitogen. 
These resules demonstrate that a similar degree of resolution of 
the disease process as that achieved by total lymphoid irradiation. 
cyclosposproine A, and monoclonal antibody therapy 111- 15.26J 
can be achieved through the usc of autoimmune splc:nocyres as an 
immunogen, rendering the recipient capable of inhibiting the ful-
minant proliferation of abnormal T-cells. Moreover, therapy with 
photoinactivated autologous lymphocytes obviates the necessity for 
introducing cyto[Qxic agents and compromising normal immune 
status. 
The role of psoralen and ultraviolet A light in enhancing the 
imlllunogeniciry of the i,~ected cells Illay he significant. Injection 
of cells alone was demonstrated to mediate a somewhat similar 
effee( but mice treated in this fashion died earlier and did not 
have reduced splenomegaly until late in the treatment protocol. In 
addition. no normalization of the response to Con A, which may 
reflect the retemion of normal lymphoid cells [24,251. was found in 
the spleens of mice treated with unmodified cells. Unmodified au-
toimmune cells were expected to mediate a similar effect to photo-
treated autoimmune cells if the treatment protocol mediated a re-
sponse directed towards cells expressing an autoreactive T -ccll 
idiorypc. The addition of psoralen and UVA to the reinfused au-
toimmune cell population served to enhance the effectiveness of 
this treatment regimen. The partial effectiveness of the il~ection of 
unmodified autoimmune splenocytes also suggests that the inhibi-
tion of the T-cell hyperplasia in treated mice is nor secondary to 
effects of un metabolized drug but is dependent on the presence of 
the intact effector cells. Further support for this comention comes 
from the cxperiment~ using lysed cells treated with psoralen and 
UVA, whcre exacerbations of the disease process was noted. 
The effect ofbysrander normal lymphocytes as well as dendritic 
cells and macrophages thar inhabit the spleen has not been studied in 
these protocols. alrhough their roles may be significant. Previous 
studies have demonstrated that myeloid cells are relatively resistant 
ro the effects of 8-methoxypsoralcn and ultraviolet A ligln !t81. 
Their comriburion to phototherapy will be the focus of future in-
vestigations. In addition. the studies of Andersson et al demon-
strated that it was possible to induce specific unresponsiveness to the 
efTeccor cells mediating skin graft rejection by treating antigen-spe-
cific lymphocytes sensitized in vitro with Freund's complete adju-
vant prior to injection into syngeneic recipients [27]. The require-
ment for adjuvant in their experiments may be overcome in our 
system by the reinfusion of phototreated bystander lymphocytes 
which gradually die and may release substantial amounts of Iym-
phokines. 
Although the underlying mechanism of this mode of therapy 
remains to be elucidared, the results indicate that this form of im-
munomodulation is companble to other rypes of T-cell directed 
modalities. Studies performed by Cohen et al 128.291 have demon-
strated that il~ection of inactivated T-cell clones capable of mediat-
ing autoimmune disease results in protection against the subsequent 
induction of the autoimmune process. In 3. similar fashion, reinfu-
sion of uncloned effector cells 10 young MRL/I mice might pennit 
the development of an autoregulatory response mounted by a rela-
tivciy int:Jct immune system. Because trearment of autoimmune 
discase with autologous photolllodified lymphocytes is clinically 
practical, further studies of this form of therapy may be of va lue in 
VOl. 94, NO.1 JANUARY 1990 
the management of autoreactive processes as well as ;I spectrum of 
T-cell mcdi:ncd dysfuncrions. 
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